Monensin sodium salt

Names

[ Name ]:
Monensin sodium salt

[Synonym ]:
Monensin Sodium (200 mg)
Monensin sodium
Coban
MONENSINSODIUM,USP
RUMENSIN
EINECS 244-941-7
monensin A sodium
Monensin Sodium Salt
Sodium Monensin
Monensin A sodium salt
monensin,monosodiumsalt
Coban45
Monensim A sodium salt

Biological Activity

[Description]:

Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis.

[Related Catalog]:

Signaling Pathways >> Anti-infection >> Bacterial

Research Areas >> Infection

[Target]

bacterial[1]

[In Vitro]

Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis. Untreated cells display 2.5% apoptosis; 48 hours treatment with 1 μM Monensin sodium salt shows 4.5% apoptosis whereas 5 μM Monensin sodium salt for 48 hours induces a greater apoptotic response (16.4%). Pretreatment with either 1 or 5 μM Monensin sodium salt for 24 hours followed by 10 μM erlotinib treatment for another 24 hours results in a marked increases in apoptotic events (14.6% and 38.7%, respectively) when compare with either Monensin sodium salt or erlotinib treatments alone. Combination of 5 μM Monensin sodium salt with 10 μM erlotinib shows the highest percentage of apoptosis (38.7%)[1].

[In Vivo]

Although the numbers of tumors do not change substantially, a significant (P=0.0144) reduction in the average size of lesions is observed in Monensin sodium salt-treated Apc+/Min mice when compare with control animals (mean 0.199 mm2 vs. 0.299 mm2). The total tumor area estimated in one animal is decreased in individuals receiving Monensin sodium salt (mean 10.16 mm2 vs. 16.46 mm2; P=0.0125). Monensin sodium salt treatment increases the numbers of apoptotic cells and cells expressing the p21 cell-cycle inhibitor at the surface area of the neoplastic outgrowths. No changes in the cell proliferation, differentiation, and tissue architecture in the healthy parts of mucosa are noted after exposure to Monensin sodium salt[2].

[Cell Assay]

One million SCC25 cells are seeded in 10-cm plates and incubated overnight to allow for attachment and recovery. The following day, cells are pretreated with 0, 1, or 5 μM Monensin sodium salt for 24 hours then treated with 10 μM erlotinib alone or in combination with Monensin sodium salt for a further 24 hours. Adherent and cells in suspension are collected by centrifugation and fixed in 3 mL of cold 80% ethanol overnight at -20°C. Before analysis, cell pellets are washed with PBS resuspended in staining buffer containing 25 μg/mL propidium iodide and 40 μg/mL RNase A and incubated for a minimum of 1 hour in the dark at room temperature[1].

[Animal admin]

Multiple intestinal neoplasia (Min) mice are used in this study. Four-week-old pups are weaned, genotyped, and randomized. The animals are divided into two groups and treated with Monensin sodium salt (10 mg/kg) or vehicle (DMSO). Daily oral applications continue for 6 weeks. In addition, six pairs of Apc+/Min mice age 7, 10, 13, 16, 19, and 22 weeks are treated with Monensin sodium salt or vehicle for 5 weeks. The mice are sacrificed and the intestines are dissected, washed in PBS, and fixed in 4% formaldehyde (v/v) in PBS for 3 days. Fixed intestines are embedded in paraffin, sectioned and stained. The number and size of the neoplastic lesions are quantified using Ellipse software[2].

[References]

[1]. Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13(11):2559-71.

[2]. Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13(4):812-22.

[Related Small Molecules]

Chemical & Physical Properties

[ Boiling Point ]:
766.3ºC at 760 mmHg

[ Melting Point ]:
267-269ºC

[ Molecular Formula ]:
C₃₆H₆₁NaO₁₁

[ Molecular Weight ]:
692.85

[ Flash Point ]:
229.2ºC

[ PSA ]:
165.43000

[ LogP ]:
2.87390

[ Vapour Pressure ]:
4.13E-27mmHg at 25°C

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H300

[ Precautionary Statements ]:
P264-P301 + P310

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ Hazard Codes ]:
T:Toxic;

[ Risk Phrases ]:
R25

[ Safety Phrases ]:
S45

[ RIDADR ]:
UN 3462 6.1/PG 2

[ WGK Germany ]:
3

[ RTECS ]:
JH2830000

[ Packaging Group ]:
II

[ Hazard Class ]:
6.1(a)

Precursor & DownStream

Precursor

DownStream

Preparation

Articles

Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions.

Int. J. Pharm. 483(1-2) , 268-77, (2015)

Cervical cancer induced by human papillomavirus (HPV) is the fourth highest mortality causing cancer in women despite the use of prophylactic vaccines. E6 targeting represents an attractive strategy t...

In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383.

Pharm. Res. 32 , 3937-51, (2015)

To assess accumulation and lysosomal sequestration of 9 drugs used in respiratory indications (plus imipramine as positive control) in the alveolar macrophage (AM) cell line NR8383.For all drugs, upta...

Interneuron- and GABA(A) receptor-specific inhibitory synaptic plasticity in cerebellar Purkinje cells.

Nat. Commun. 6 , 7364, (2015)

Inhibitory synaptic plasticity is important for shaping both neuronal excitability and network activity. Here we investigate the input and GABA(A) receptor subunit specificity of inhibitory synaptic p...